Tradestie Institutional Equity Comparison Engine

DMAC vs COCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DMAC N/M vs COCP N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -3063.6% ยท YoY +0.0% vs +26.9%
Momentum & Technical Winner DMAC
1Y +55.3% vs -3.0% ยท 52W Pos 55% vs 19%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs UNCLASSIFIED (N/A IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% COCP -2.96% Spread: +58.22 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue COCP Revenue DMAC Op. Margin COCP Op. Margin Margin Edge
FY2011 N/A $10M N/A -30.6% COCP
FY2018 $0M N/A -1352.2% N/A DMAC
FY2019 N/A $10M N/A -737.4% COCP
FY2020 N/A $0M N/A -476.0% COCP

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (4) vs COCP (3)
Institutional Metric DMAC COCP Criterion Row Winner
Market Capitalization Scale $503.1M $19.6M Larger Scale DMAC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +26.9% Higher Growth COCP
Operating Margin (TTM) Profitability 0.0% -3063.6% Higher Margin DMAC
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -114.6% -311.7% Higher ROE DMAC
52-Week Range Position Momentum 55% ($5โ€“$11) 19% ($1โ€“$2) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite COCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs COCP Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.